[1] Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: A review. JAMA, 2018,319(17):1802-1813. [2] Ligat G, Schuster C, Baumert TF. Hepatitis B virus core variants, liver fibrosis, and hepatocellular carcinoma. Hepatology, 2019,69(1):5-8. [3] Li TY, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World JGastroenterol, 2019,25(27): 3527-3537. [4] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019,156(6):1717-1730. [5] Ekin N, Ucmak F, Ebik B, et al. GPR, King's score and S-index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients. Acta Gastroenterol Belg, 2022,85(1):62-68. [6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32. [7] 周琨,郑瑞丹,咸建春,等. 从常规指标中建立肝纤维化非创伤性诊断模型. 肝脏,2008,13(5):362-367. [8] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年). 中华肝脏病杂志,2019,27(9):657-667. [9] 国家卫生健康委员会.中国卫生健康统计年鉴2019年.中国协和医科大学出版社,2019:14-17. [10] 张茜,胡鹏. 慢性乙型肝炎治愈新药研究进展. 实用肝脏病杂志,2019,22(3):313-317. [11] Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol, 2018,26(1):33-42. [12] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells, 2020,9(4):875. [13] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol, 2021,18(3):151-166. [14] Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother, 2020,21(13):1637-1650. [15] 安红杰,耿华,葛志胜,等. 瞬时弹性成像技术在慢性乙型肝炎肝纤维化诊断及预后评估中的价值. 中华医院感染学杂志,2020,30(22):3443-3447. [16] Midia M, Odedra D, Shuster A, et al. Predictors of bleeding complications following percutaneous image-guided liver biopsy: a scoping review. Diagn Interv Radiol, 2019,25(1):71-80. [17] Tag-Adeen M, Omar MZ, Abd-Elsalam FM, et al. Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes. Medicine (Baltimore), 2018,97(6):9781. [18] Li B, Zhang L, Zhang Z, et al. A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis.Eur J Gastroenterol Hepatol, 2019,31(2):218-223. [19] Wang Z, Zhou Y, Yu P, et al. Retrospective evaluation of non-invasive assessment based on routine laboratory markers for assessing advanced liver fibrosis in chronic hepatitis B patients.Int J Gen Med, 2022,15:5159-5171. [20] Kawamura N,Imajo K, Kalutkiewicz KJ, et al. Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2022,76(1):186-195. [21] Ouyang GX, Zhang YM, Zhu SL, et al. A novel, non-invasive model for diagnosing liver fibrosis stage in patients with hepatocellular carcinoma. Sci Rep, 2018,8(1):13074. |